http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108159038-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-655 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2018-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108159038-B |
| titleOfInvention | Pharmaceutical composition and application thereof in preparation of medicine for treating tumor multidrug resistance |
| abstract | The invention discloses a pharmaceutical composition and application thereof in preparing a medicine for treating tumor multidrug resistance, belongs to the field of biological medicine, and the pharmaceutical composition contains chlorogenic acid and coumaroyl quinic acid and can be used for preparing a tumor multidrug resistance reversal agent and a PD-1/PD-L1 inhibitor. Chlorogenic acid and coumaroyl quinic acid are used together, a synergistic effect can be achieved, the chlorogenic acid has a good effect of reversing drug resistance on tumor cell lines with multi-drug resistance generated by chemotherapeutic drugs and immunotherapy drugs, the expression of PD-1/PD-L1 in transplanted tumor tissues of drug-resistant B16 melanoma and drug-resistant Lewis lung cancer mice can be effectively inhibited, and the proliferation effect on cells generating drug-resistant B16 melanoma mice and CD4+ T and CD8+ T of Lewis lung cancer mice can be effectively achieved. |
| priorityDate | 2018-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 57.